Expression level and Clinical Significance of Serum SE-CAD and Matriptase in Patients with Acute Myeloid Leukemia.
10.19746/j.cnki.issn.1009-2137.2019.03.018
- Author:
Lian ZHAO
1
;
Zi-Yang ZHENG
2
;
Min ZHONG
3
Author Information
1. Department of Clinical Laboratorial Examination, The First Affiliated Hospital of Hainan Medical College, Haikou 570102, Hainan Province, China,E-mail:ssjjkoyss@163.com.
2. Central Laboratory, The First Affiliated Hospital of Hainan Medical College, Haikou 570102, Hainan Province, China.
3. Department of Hematology, The First Affiliated Hospital of Hainan Medical College, Haikou 570102, Hainan Province, China,E-mail：ZHongMinhn40@163.com.
- Publication Type:Journal Article
- MeSH:
Cadherins;
Humans;
Leukemia, Myeloid, Acute;
Prognosis;
Serine Endopeptidases
- From:
Journal of Experimental Hematology
2019;27(3):753-757
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the expression level of the serum soluble E cadherin (SE-CAD) and Matriptase and its clinical significance for evaluation of the disease condtions and prognosis in patients with acute myeloid leukemia (AML).
METHODS:One hundred and ten patients diagnosed as AML in our hospital were divided into 3 groups: newly diagnosed group (38 cases), remission group (40 cases) and recurrence group (32 cases). The expression levels of serum matriptase were detected by Western blot, and the expression levels of serum SE-CAD were detected by ELISA. The serum levels of serum SE-CAD and matriptase among 3 groups were compared. Followin-up for one year, according to the outcome of patients, all the patients were divided into 2 groups: the survival group and death group. The serum levels of SE-CAD and Matriptase were compared between 2 groups. The correlation of serum levels of SE-CAD and matriptase with the survival of AML patients was analyzed by multivariate Logistic analysis. The evaluation value of the serum levels of SE-CAD and matriptase for the prognosis of the patients with AML were analyzed by receiver operating characteristic curves (ROC).
RESULTS:The serum levels of SE-CAD and matriptase were siginificantly different among 3 groups (P＜0.05). The serum levels of SE-CAD and matriptase in remission group were lowest (P＜0.05), and the serum levels of SE-CAD and matriptase were not different between newly diagnoses and recurrence groups (P＞0.05). Multivariate Logistic analysis showed that the serum levels of SE-CAD and matriptase were independent risk factors for the prognosis of AML patients (OR=3.157, P＜0.05, OR=2.426, P＜0.05). By follow-up for 1 year, the serum expression levels of SE-CAD and Matriptase in survival group were lower than that in death group. ROC curve showed that when the cut-off value of matriptase level was 0.73 and SE-CAD level was 3.42 ng/ml, the AUC of predictions for the poor prognosis in AML patients was 0.849 (P＜0.05), the sensitivity was 85.6% (95%CI: 0.810~0.924) and specificity was 89.6% (95%CI: 0.849~0.941).
CONCLUSION:The serum levels of SE-CAD and matriptase can perfectly evaluate the condition and short-term prognosis of the patients with AML.
